Quarterly ResultMay 5, 2026, 04:18 PM
Carlsmed Q1 Revenue Jumps 58% to $16.1M; Net Loss $(8.7)M
AI Summary
Carlsmed, Inc. reported a significant increase in revenue for the first quarter of 2026, reaching $16.1 million, a 58% rise year-over-year. Despite this growth, the company's net loss widened to $8.7 million. The quarter also saw the exercise of outstanding warrants and continued progress in its cervical spine fusion product line, including the first personalized corra cervical plating procedure. The company believes its existing cash on hand will be sufficient for at least the next 12 months.
Key Highlights
- Revenue increased 58% to $16.1 million for Q1 2026 from $10.2 million in Q1 2025.
- Gross profit rose 63% to $12.4 million in Q1 2026 from $7.6 million in Q1 2025.
- Net loss for Q1 2026 was $(8.7) million, compared to $(5.7) million in Q1 2025.
- Net loss per share improved to $(0.32) in Q1 2026 from $(1.47) in Q1 2025.
- Cash, cash equivalents, and restricted cash totaled $73.1 million as of March 31, 2026.
- Customers Bank exercised Series B and C Warrants, issuing 30,366 common shares.
- First personalized corra cervical plating procedure completed in February 2026.
- Company expects to commercially launch corra Cervical Plating System by December 2026.
Price Impact
More from CARL